Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

@article{Stahl2009WhichCF,
  title={Which comes first: atypical antipsychotic treatment or cardiometabolic risk?},
  author={Stephen M Stahl and Laurence Mignon and J. M. Meyer},
  journal={Acta Psychiatrica Scandinavica},
  year={2009},
  volume={119}
}
Objective:  To provide an overview for practicing clinicians on the pharmacological basis of cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness, to propose hypotheses to explain these risks and to give tips for managing cardiometabolic risk during antipsychotic treatment. 
Understanding antipsychotic-induced weight gain and other metabolic issues
TLDR
Some of the more commonly accepted hypotheses for the reasons antipsychotics contribute towards metabolic disorders are explored and the potential implications for practice are discussed.
Psychological factors of cardiometabolic risk: History and modern state
The history of psychosomatic research and current studies of psychological infl uences on cardiometabolic risk are reviewed. Personality, psychopathological, situational and cognitive-behavioural
RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND‐GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY
Second‐generation antipsychotics (SGA) augmentation treatment has showed better efficacy in patients with major depressive disorder (MDD). However, the association between SGA and diabetes mellitus
Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent‐onset bipolar disorder
This study aims to investigate the association between early treatment with psychotropic medications and the development of medical comorbidities in pediatric patients who develop bipolar disorder
Safety issues related to the use of prescription drugs in patients with chronic diseases: a bibliographic review
Purpose A literature review was conducted with the aim of investigating the impact of treatments associated with an increased risk of hypertension, hyperglycaemia, hyperkalaemia, bone fracture and
Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play.
Schizophrenia: A major risk factor for cardiovascular disease
TLDR
The factors behind the increased risk of cardiovascular disease in people with SMIs are reviewed, including lifestyle factors compounding a pre-existing vulnerability to metabolic disorders and also side-effects of antipsychotic drugs used in treatment of their condition.
Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?
TLDR
The characteristics of a new drug, asenapine, that may improve adherence in patients as a result of a distinctive receptor profile that may be associated with fewer side effects than other second-generation antipsychotic drugs are reviewed.
Metabolic syndrome with the atypical antipsychotics.
TLDR
In addition to behavioral therapy, emerging data suggest that pharmacological therapy, most notably metformin, is efficacious in the treatment and possibly prevention of SGA-associated metabolic derangements.
Management of elevated blood cholesterol in the psychiatric patient: What's new in the guidelines?
TLDR
4 specific patient populations at high risk for ASCVD that should be considered candidates for therapeutic lifestyle changes and pharmacotherapy are described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Metabolic syndrome and schizophrenia.
  • J. Thakore
  • Medicine
    The British journal of psychiatry : the journal of mental science
  • 2005
Metabolic syndrome - a cluster of disorders comprising obesity (central and abdominal), dyslipidaemias, glucose intolerance, insulin resistance (or hyperinsulinaemia) and hypertension - is highly
Atypical antipsychotic‐induced diabetes mellitus: an update on epidemiology and postulated mechanisms
TLDR
A rare case of hyperosmolar hyperglycaemic syndrome in a young man with schizophrenia is emphasized and proposed mechanisms for the development of antipsychotic‐associated diabetes mellitus are discussed.
Hyperlipidemia following treatment with antipsychotic medications.
TLDR
It is suggested that most commonly prescribed antipsychotic medications increase the risk of developing hyperlipidemia in patients with schizophrenia or mood disorders.
A typical Antipsychotic Induced Weight Gain: Pathophysiology and Management
TLDR
Drug induced obesity provides a unique opportunity to psychiatrists to understand this clinically important problem and management of weight gain is a difficult problem.
Dyslipidemia Independent of Body Mass in Antipsychotic-Treated Patients Under Real-Life Conditions
TLDR
Findings indicate a primary effect of APs on lipid regulation, important in understanding their mechanism of action, and with clinical implications, in subjects with severe mental disorders.
Dosing Atypical Antipsychotics
The task of prescribing, dosing, and switching antipsychotics is generally characterized by a process of trial and error, often resulting in suffering from side effects and/or lack of response while
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
TLDR
The results suggest that leptin may be associated with olanzapine- and clozAPine-induced weight gain and that quetiapine appears to have modest influence and risperidone seems to have minimal influence on leptin and triglyceride levels and weight gain compared with o Lanzapines and clozoapine.
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
TLDR
Both the rate and incidence of clinically relevant metabolic syndrome differ according to the choice of antipsychotic agent, and the association between metabolic syndrome and treatment warrants careful consideration in the choices of antippsychotic agents.
Atypical antipsychotic induced weight gain: pathophysiology and management.
TLDR
Drug induced obesity provides a unique opportunity to psychiatrists to understand this clinically important problem and education, diet control and simple behavioral measures may prevent excessive weight gain.
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
TLDR
A review examines the potential contribution of different receptors to metabolic side effects associated with atypical antipsychotic treatment for all seven agents currently marketed in the United States and another agent in clinical development at the time of this publication.
...
1
2
3
4
5
...